ArticleJournal of medical virology2025
Clinical Characteristics and Treatment Efficacy in Patients With SARS-CoV-2 Positivity After Nirmatrelvir-Ritonavir Therapy.
Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era.The Journal of antimicrobial chemotherapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Nirmatrelvir-ritonavir (NMV-r) has been widely used to treat coronavirus disease 2019 (COVID-19) for a standard period of 5-days. However, there are increasing reports of patients with persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity after the standard 5-day course of NMV-r treatment. Moreover, the clinical characteristics of these patients and the efficacy of extending NMV-r treatment duration are not fully understood. We conducted a prospective study involving hospitalized patients with COVID-19. In total, 310 patients were included: 133 with SARS-CoV-2 RNA positivity after completion of the standard course of NMV-r (positive group) and 177 without SARS-CoV-2 positivity (negative group). A subset of patients (n = 37) in the positive group extended the treatment with NMV-r. Patients in the positive group had higher severity scores, neutrophil counts, lactate dehydrogenase levels, and viral loads at admission. Following the standard 5-day NMV-r course, the positive group showed a significantly increased risk of composite disease progression outcomes (hazard ratio [HR] 3.35, 95% confidence interval [CI]: 2.07-5.44; p < 0.0001). This group also demonstrated higher risks of 28-day all-cause mortality, initiation of invasive mechanical ventilation, intensive care unit (ICU) admission and prolonged hospitalization. However, no significant differences in clinical outcomes were observed between the standard and the extended treatment groups in the unadjusted analysis. After adjustment for baseline characteristics, the extended treatment group demonstrated significantly better outcomes compared with the standard treatment group. Specifically, the extended treatment group had lower rates of composite disease progression (HR: 0.39, 95% CI: 0.20-0.79; p = 0.009), invasive mechanical ventilation (HR: 0.24, 95% CI: 0.08-0.73; p = 0.01), and ICU admission (HR: 0.15, 95% CI: 0.02-0.94; p = 0.04), along with a shorter length of hospital stay (HR: -13.54, 95% CI: -26.01 to -1.07; p = 0.033). SARS-CoV-2 positivity after NMV-r treatment is common and associated with worse clinical outcomes. Extending NMV-r therapy may reduce disease progression risk; this finding requires confirmation in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.